BioXcel Therapeutics Inc. (BTAI)
NASDAQ: BTAI
· Real-Time Price · USD
1.70
0.14 (8.97%)
At close: Jun 16, 2025, 3:59 PM
1.69
-0.59%
Pre-market: Jun 17, 2025, 06:29 AM EDT
8.97% (1D)
| Bid | 1.6 |
| Market Cap | 10.3M |
| Revenue (ttm) | 1.85M |
| Net Income (ttm) | -40.06M |
| EPS (ttm) | -11.12 |
| PE Ratio (ttm) | -0.15 |
| Forward PE | -0.13 |
| Analyst | Buy |
| Ask | 1.75 |
| Volume | 106,836 |
| Avg. Volume (20D) | 307,804 |
| Open | 1.50 |
| Previous Close | 1.56 |
| Day's Range | 1.53 - 1.71 |
| 52-Week Range | 1.17 - 25.12 |
| Beta | -0.13 |
About BTAI
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol BTAI
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for BTAI stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 months ago
+7.73%
BioXcel Therapeutics shares are trading higher aft...
Unlock content with
Pro Subscription
3 months ago
+22.99%
BioXcel Therapeutics shares are trading higher after the company announced it has reached 33% enrollment in its 200-patient SERENITY At-Home trial.
5 days ago · https://www.defenseworld.net
Squarepoint Ops LLC Acquires 48,336 Shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI)Squarepoint Ops LLC grew its stake in shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Free Report) by 203.9% during the fourth quarter, according to the company in its most recent 13F filing...
